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The purpose of this study was to estimate in all randomised trials the relative risk of overall response rate (ORR), clinical benefit (CB),
time to progression (TTP), overall survival (OS), and toxicity of aromatase inhibitors (AI), compared with tamoxifen (Tam) as first-line
endocrine therapy in postmenopausal metastatic breast cancer (PMBC) women. Prospective randomised studies were searched
through computerised queries of MEDLINE, EMBASE, and the American Society of Clinical Oncology (ASCO) abstract database.
Relative risk, 95% confidence interval, and heterogeneity were derived according to the inverse variance and Mantel–Haenszel
method and Q statistics. Six phase III prospective randomised trials including 2787 women were gathered. A significant advantage in
ORR (P¼0.042), TTP (P¼0.007), and CB (P¼0.001) in favour of AI over Tam was detected at the fixed effects model. These
results were not significant at the random effects model, owing to the significant heterogeneity. On the contrary, no difference was
registered for OS (P¼0.743) with no significant heterogeneity. Regarding toxicity, Tam caused more frequently thromboembolic
events (P¼0.005) and vaginal bleeding (P¼0.001) compared with AI. Aromatase inhibitors appear to be superior to Tam as first-line
endocrine option in PMBC women. Owing to a component of variability between the six studies analysed, the random effects
estimates differed from corresponding fixed ones. Investigators should assess heterogeneity of trial results before deriving summary
estimates of treatment effect.
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Two-thirds of breast tumours express oestrogen receptor and
women having cancers with this characteristic are suitable
candidates for endocrine therapy (ET) (Forbes, 1997). Tamoxifen
(Tam) has been considered for a long time the drug of choice for
postmenopausal women with hormone receptor-positive meta-
static breast cancer (MBC). However, Tam is associated with an
increased incidence of endometrial cancer and thromboembolic
events (TE), and many tumours become resistant to it during
treatment (DeFriend et al, 1994). Nowadays, the aromatase
inhibitors (AI) are considered the treatment of choice for
postmenopausal women with newly diagnosed metastases from
hormone receptor-positive breast cancer, either in Tam-naı ¨ve
patients or in those progressing after failing or while on adjuvant
Tam. The AI remarkably suppress plasma oestrogen levels in
postmenopausal women by inhibiting or inactivating aromatase,
the enzyme responsible for the synthesis of oestrogens from
androgenic substrates. Third-generation AI (tgAI), including
anastrozole, letrozole, and exemestane, have replaced aminoglu-
tethimide in the treatment of postmenopausal patients with MBC
because of their considerably lower toxicity. In addition, tgAI have
been reported to be more effective and/or less toxic than megestrol
acetate (Buzdar et al, 1998, 2001a; Dombernowsky et al, 1998;
Kaufmann et al, 2000) and Tam (Bonneterre et al, 2000, 2001;
Mouridsen et al, 2001, 2003; Nabholtz et al, 2000, 2003; Paridaens
et al, 2004). As tgAI have been approved as first-line ET for
postmenopausal women with MBC, the issue concerning the
optimal sequence of ET has become more challenging. In fact, as
AI are more and more frequently used as adjuvant ET, the still
open issue concerning the optimal ET sequence will be likely re-
challenged in the next future.
A meta-analysis based on patient survival data found a 21%
reduction in the risk of death for patients treated with AI
(anastrozole, letrozole, and exemestane) compared with those
given megestrol (P¼0.0011) (Messori et al, 2000). On the contrary,
a pooled analysis has recently suggested that all AI as second-line
ET compared with megestrol for postmenopausal MBC patients do
not seem to add any significant advantage in terms of overall
response rate (ORR) or time to progression (TTP) (Carlini et al,
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s2005). At the present time, the issue as to whether an AI can be
more effective than the others remains controversial. Letrozole
has been shown to reduce oestrogen levels to a greater degree than
the other AI (Boeddinghaus and Dowsett, 2001). Anastrozole has
been reported to have greater selectivity for aromatase (Buzdar
2001b), but it is still uncertain whether these laboratory findings
could affect the clinical decision of preferring one drug instead of
another.
The aim of this meta-analysis was to estimate in all published
randomised trials the relative risk (RR) of ORR, TTP, clinical
benefit (CB), overall survival (OS) and, whenever possible, adverse
events of AI compared with Tam as first-line ET in postmeno-
pausal women with MBC.
MATERIALS AND METHODS
Outcome definition
We considered the AI as experimental arm and Tam as standard
comparator arm. Analysis was conducted in order to find out
eventual significant differences in primary and secondary out-
comes. Primary outcomes were (1) ORR and (2) TTP. The
secondary outcomes were OS, CB, and toxicity, evaluated in at least
three trials. In particular, we looked at hot flushes (HF), nausea
(N), vomiting (V), TEs, vaginal bleeding (VB), and musculo-
skeletal pain (MSP). All calculations were independently per-
formed by two different investigators. The definition of CB (British
Breast Group, 1974) was the same across all trials.
Trial identification criteria
We collected all the prospective randomised trials published as
formal papers in peer-reviewed journals or as abstracts in the
international congresses proceedings until 31 December, 2004
(Perez Carrion et al, 1994; Falkson and Falkson, 1996; Thurlimann
et al, 1996; Bonneterre et al, 2000; Nabholtz et al, 2000; Mouridsen
et al, 2001; Milla-Santos et al, 2003; Paridaens et al, 2004)
(Table 1). In these trials, postmenopausal patients affected by MBC
relapsing after adjuvant therapy were randomised to receive AI vs
standard treatment (Tam). Letters/editorials, studies on AI given
as adjuvant/neoadjuvant ET were ruled out.
Search strategy
Relevant studies were searched through computerised queries of
MEDLINE (available from URL: www.ncbi. nlm.nih.gov/PubMed),
EMBASE (available from URL: www.embase.com), and the
American Society of Clinical Oncology (ASCO) abstract database
(available from URL: www.asco.org). Keywords used for research
were metastatic breast cancer, aromatase inhibitors, first-line, AI,
steroidal, non-steroidal, anastrozole, fadrozole, letrozole, exemes-
tane, formestane, review, metanalysis, meta-analysis, pooled
analysis, randomised, phase III, comprehensive review, systematic
review, hormonal, and endocrine. Beyond computer browsing,
review and original papers were also scanned in the references
section to look for missing trials. From each study we obtained (1)
rate and number of complete and partial responses, (2) CB (British
Breast Group, 1974), (3) median TTP, (4) median OS and (5) rate
and number of toxicity events.
Statistical methods
The log of RR was estimated for each considered end point.
Estimated events at 6 months were used when considering TTP
and OS. These RRs were combined across the studies, giving
weight to the number of events in each of the two treatment groups
in each separate study using the Mantel–Haenszel procedure and
the inverse variance method; both estimations were performed
assuming a fixed effects model (FEM) and a random effects model
(REM) (Parmar et al, 1998). The heterogeneity between trials was
tested with the Q statistics, computing the square distance of each
study from the combined effect and weighting these values with
the inverse of variance of each study (Takkouche et al, 1999). The
Q statistics was then compared with the w
2 distribution with k 1
degrees of freedom, where k is the number of studies. All
calculations were performed with the Comprehensive Meta-
analysis software (version 1.0.23, Biostat, Englewood, NJ, USA)
(Bria et al, 2005).
RESULTS
Selected trials
The eight prospective randomised trials comparing AI vs Tam
(Perez Carrion et al, 1994; Falkson and Falkson, 1996; Thurlimann
et al, 1996; Bonneterre et al, 2000; Nabholtz et al, 2000; Mouridsen
et al, 2001; Milla-Santos et al, 2003; Paridaens et al, 2004) were
conducted between 1994 and 2004, and included 3238 women
(Table 1). Globally, 1615 patients were enrolled in the AI arm and
1623 in Tam arm. The median number of patients per trial was 362
(range 80–907). The median follow-up time, when reported, varied
much among trials (between 5.1 and 36 months) (Table 1). In the
AI arm, TTP ranged between 7.1 and 18 months, and in the Tam
arm, between 5.6 and 9.8 months. In the AI arm, the OS range
Table 1 Characteristics of the studies
RCTs Year Pts Arms Primary/secondary end points
Median follow-
up (months) Key results
Perez Carrion 1994 409 FOR vs TAM ORR (UICC)/TTP, TTF, OS, safety NR No difference in ORR and OS, longer TTP and
TTF in the TAM arm
Thurlimann 1996 212 FDZ vs TAM ORR (WHO)/TTF, OS, safety 36 Not double-blinded, no difference in ORR and
OS, longer TTF in the TAM arm
Falkson 1996 80 FDZ vs TAM ORR (ECOG)/TTF, OS, safety 5.1 No difference in ORR, TTF, and OS
Nabholtz 2000 353 ANA vs TAM ORR (UICC), TTP, safety/TTF, CB, OS 17.7 No difference in ORR, longer TTP, and higher CB
in the ANA arm
Bonneterre 2000 668 ANA vs TAM ORR (UICC), TTP, safety/TTF, CB, OS 19 No difference in ORR, TTP, and CB
Mouridsen 2001 907 LTZ vs TAM TTP/ORR (UICC), TTF, CB, OS, safety 32 Longer TTP, higher ORR and CB in the LTZ arm
Milla Santos 2003 238 ANA vs TAM CB, ORR (WHO), TTP, OS, safety 13.3 Longer TTP and OS, higher CB, in the ANA arm
Paridaens 2004 371 EXE vs TAM PFS/OS, safety NR Longer PFS, higher ORR in the EXE arm
Total 3238
ANA¼anastrozole; CB¼clinical benefit; EXE¼exemestane; FDZ¼fadrozole; FOR¼formestane; LTZ¼letrozole; NR¼not reported; ORR¼overall response rate;
OS¼overall survival; PFS¼progression-free survival; pts¼patients; RCTs¼randomised clinical trials; TAM¼tamoxifen; TTF¼time to treatment failure; TTP¼time to
progression.
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svaried between 17.4 and 39.2 months, and in the Tam arm,
between 16 and 40 months. In the AI arm, CB ranged between 50
and 83%, and in the Tam arm, between 38 and 75.7%. Hot flushes
rate was reported in all trials (3238 patients), N in six trials (Perez
Carrion et al, 1994; Thurlimann et al, 1996; Bonneterre et al, 2000;
Nabholtz et al, 2000; Mouridsen et al, 2001; Paridaens et al, 2004)
(2920 patients), V in five trials (Perez Carrion et al, 1994;
Thurlimann et al, 1996; Bonneterre et al, 2000; Nabholtz et al,
2000; Paridaens et al, 2004) (2012 patients), TE in six trials
(Thurlimann et al, 1996; Bonneterre et al, 2000; Nabholtz et al,
2000; Mouridsen et al, 2001; Milla-Santos et al, 2003; Paridaens
et al, 2004) (2749 patients), VB in four trials (Bonneterre et al,
2000; Nabholtz et al, 2000; Milla-Santos et al, 2003; Paridaens
et al, 2004) (1630 patients), and MSP in four trials (Bonneterre et al,
2000; Nabholtz et al, 2000; Milla-Santos et al, 2003; Paridaens et al,
2004) (2299 patients). The primary and secondary end points are
indicated in Table 1. All arms within each trial were well balanced
for pretreatment characteristics of the patients.
For our meta-analysis, we selected only the phase III studies
published as original papers in peer-review journals. These studies
(Perez Carrion et al, 1994; Thurlimann et al, 1996; Bonneterre et al,
2000; Nabholtz et al, 2000; Mouridsen et al, 2001; Milla-Santos
et al, 2003) globally included 2787 women. The trial by Falkson
and Falkson (1996), which was a randomised phase II study, was
excluded. The study by Paridaens et al (2004), which was a large
randomised phase III trial presented at the 2004 ASCO annual
meeting but published exclusively in the abstract format, was
included only in the comparisons (efficacy and toxicity) between
tgAI vs Tam.
Combined analysis
All outcomes and their statistical significance are listed in Table 2.
Risk ratios have to be interpreted as follows: regarding ORR and
CB, RR more than 1.0 favours AI, whereas RR less than 1.0 favours
Tam; concerning TTP and OS, RR less than 1.0 favours AI, whereas
RR more than 1.0 favours Tam (event-based analysis, see Statistical
methods).
We compared AI vs Tam in the overall population (2787
patients), using the FEM first. A significant advantage in ORR in
favour of AI over Tam was detected (RR¼1.13, 95% confidence
interval (CI) 1.00–1.28, P¼0.042) (Table 2 and Figure 1). The
same impact in favour of AI was seen for TTP (2549 patients),
where RR was 0.88 (95% CI 0.80–0.96, P¼0.007) (Table 2 and
Figure 2). Moreover, concerning CB, a statistically significant
advantage in favour of AI compared with Tam was observed (RR
Table 2 Efficacy: aromatase inhibitors vs tamoxifen (FEM and REM)
RCTs Pts RR (FEM) RR (REM) 95% CI (FEM) 95% CI (REM) P (FEM) Het. P (REM)
ORR 6 2787 1.13 1.11 1.00, 1.28 0.89, 1.37 0.042 0.03 0.343
TTP 5 2549 0.88 0.92 0.80, 0.96 0.68, 1.26 0.007 o0.0001 0.637
CB 6 2787 1.11 1.13 1.04, 1.19 0.96, 1.33 0.001 o0.0001 0.123
OS 6 2787 0.97 0.79, 1.18 0.743 0.98
CI¼confidence intervals; FEM¼fixed effects model; Het¼heterogeneity; ORR¼overall response rate; OS¼overall survival; Pts¼patients; RCTs¼randomised clinical trials;
REM¼random effects model; RR¼relative risk ratio; TTP¼time to progression.
Citation Year NTotal
Perez-Carrion
Thurlimann
Nabholtz
Bonneterre
Mouridsen
Milla-Santos
Paridaens
1994
1996
2000
2000
2001
2003
2004
409
212
353
668
907
238
371
3158
3158
Fixed
Random
Combined (7)
Combined (7)
P-value
0.508
0.223
0.336
0.930
0.001
0.132
0.004
0.003
0.132
0.1 0.2 0.5 1 2 5 10
Favours TAM Favours AI
Figure 1 Aromatase inhibitors vs tamoxifen: ORR. AI: aromatase inhibitors; TAM: tamoxifen; Ntot: total number of patients; RR: relative risk; Fixed: fixed
effects model; Random: random effects model; ORR: overall response rate.
First-line aromatase inhibitors vs tamoxifen
G Ferretti et al
1791
British Journal of Cancer (2006) 94(12), 1789–1796 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s1.11, 95% CI 1.04–1.19, P¼0.001). On the contrary, no significant
difference was registered for OS (RR 0.97, 95% CI 0.79–1.18,
P¼0.743) (Table 2). A significant heterogeneity for ORR (0.03),
TTP (o0.0001), and CB (o0.0001) was registered using the FEM
(Table 2). At the REM, the significant improvement in ORR, TTP,
and CB in favour of AI over Tam was not confirmed. By contrast,
no significant heterogeneity was observed regarding OS estimates
(Table 2).
Comparing non-steroidal AI (nsAI) vs Tam using the FEM, a
significant advantage in ORR favouring nsAI vs Tam was
registered (RR¼1.23, 95% CI 1.07–1.42, P¼0.003) (Table 3).
The same advantage in favour of nsAI was seen for TTP, where
RR was 0.77 (95% CI 0.69–0.86, P¼o0.0001). A statistically
significant result was observed also for CB in favour of nsAI over
Tam (RR 1.21, 95% CI 1.12–1.31, Po0.0001). No significant
difference was registered for OS (RR 0.94, 95% CI 0.75–1.78,
P¼0.599) (Table 3). A significant heterogeneity for TTP (0.002)
and CB (0.005) was registered at the FEM (Table 3). When the REM
was used, only the improvement in CB was confirmed. No
significant heterogeneity was observed regarding OS estimates
(Table 3).
Comparing tgAI vs Tam by the fixed effects estimate (FEM), a
significant advantage in ORR favouring tgAI vs Tam was observed
(RR¼1.28, 95% CI 1.13–1.44, Po0.0001) (Table 4). The same
advantage in favour of tgAI was seen for TTP, where RR was 0.76
(95% CI 0.69–0.84, Po0.0001). A statistically significant advantage
was observed also for CB in favour of tgAI over Tam (RR 1.23, 95%
CI 1.14–1.32, Po0.0001). No significant difference was registered
for OS (RR 0.93, 95% CI 0.76–1.15, P¼0.529) (Table 4). A
significant heterogeneity for TTP (0.004) and CB (0.008) was
registered at the FEM (Table 4). Using the REM, the significant
improvement in TTP and CB in favour of AI over Tam was
confirmed. No significant heterogeneity was observed regarding
OS estimates (Table 4).
Regarding toxicity at the FEM, Tam caused more frequently TE
(RR 0.53, 95% CI 0.34–0.82, P¼0.005) and VB (RR 0.33, 95% CI
Citation Year NTotal
Perez-Carrion
Thurlimann
Nabholtz
Bonneterre
Mouridsen
Paridaens
1994
1996
2000
2000
2001
2004
409
212
353
668
907
371
2920
2920
Fixed
Random
Combined (6)
Combined (6)
P-value
0.041
0.100
0.000
0.921
0.000
0.002
0.000
0.354
0.1 0.2 0.5 1 2 5 10
Favours AI Favours TAM
Figure 2 Aromatase inhibitors vs tamoxifen: TTP. AI: aromatase inhibitors; TAM: tamoxifen; Ntot: total number of patients; RR: relative risk; Fixed: fixed
effects model; Random: random effects model.
Table 3 Efficacy: non-steroidal aromatase inhibitors vs tamoxifen (FEM and REM)
RCTs Pts RR (FEM) RR (REM) 95% CI (FEM) 95% CI (REM) P (FEM) Het. P (REM)
ORR 4 2166 1.23 1.07, 1.42 0.003 0.10
TTP 3 1928 0.77 0.76 0.69, 0.86 0.55, 1.05 o0.0001 0.002 0.098
CB 4 2166 1.21 1.25 1.12, 1.31 1.03, 1.50 o0.0001 0.005 0.018
OS 4 2166 0.94 0.75, 1.78 0.599 0.94
CI¼confidence intervals; FEM: fixed effects model; Het¼heterogeneity; ORR¼overall response rate; OS¼overall survival; Pts¼patients; RCTs¼randomised clinical trials;
REM¼random effects model; RR¼relative risk ratio; TTP¼time to progression.
Table 4 Efficacy: third-generation aromatase inhibitors vs tamoxifen (FEM and REM)
RCTs Pts RR (FEM) RR (REM) 95% CI (FEM) 95% CI (REM) P (FEM) Het. P (REM)
ORR 5 2537 1.28 1.13, 1.44 o0.0001 0.12
TTP 4 2299 0.76 0.74 0.69, 0.84 0.58, 0.94 o0.0001 0.004 0.015
CB 5 2537 1.23 1.26 1.14, 1.32 1.09, 1.46 o0.0001 0.008 0.0002
OS 5 2537 0.93 0.76, 1.15 0.529 0.98
CI¼confidence intervals; FEM¼fixed effects model; Het¼heterogeneity; ORR¼overall response rate; OS¼overall survival; Pts¼patients; RCTs¼randomised clinical trials;
REM¼random effects model; RR¼relative risk ratio; TTP¼time to progression.
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s0.17–0.65, P¼0.001) (Table 5 and Figures 3 and 4). No significant
difference was observed in HF (P¼0.171), N (P¼0.547), V
(P¼0.686), and MSP (P¼0.598) (Table 5). Similar results were
observed comparing nsAI vs Tam (Table 6) or tgAI vs Tam
(Table 7). Excluding HF, no significant heterogeneity was
registered concerning toxicity, in particular with respect to TE
and VB (Table 4). Regarding HF reported using nsAI or tgAI vs
Tam, the findings reported by the FEM were confirmed at the
REM.
DISCUSSION
The AI have been reported to be superior to Tam as initial therapy
for postmenopausal women with MBC (Nabholtz et al, 2000;
Bonneterre et al, 2001; Mouridsen et al, 2001, 2003; Paridaens et al,
2004). Our analysis of abstracted data coming from six trials using
AI as first-line endocrine option in comparison with Tam in
postmenopausal women with MBC detected a statistically sig-
nificant improvement in ORR, CB, and TTP in favour of AI over
Tam (FEM). These results were not significant at the REM, owing
to the strongly significant heterogeneity (Table 2 and Figure 1 and
Table 5 Toxicity: aromatase inhibitors vs tamoxifen (FEM)
RCTs Pts RR 95% CI P Het.
HF 6 2787 1.11 0.95, 1.30 0.171 0.06
Nausea 5 2549 0.94 0.78, 1.13 0.547 0.67
Vomiting 4 1642 1.08 0.72, 1.62 0.686 0.49
TE 5 2378 0.53 0.34, 0.82 0.005 0.42
VB 3 1259 0.33 0.17, 0.65 0.001 0.71
MSP 3 1928 1.05 0.87, 1.26 0.598 0.79
CI¼confidence intervals; FEM¼fixed effects model; Het¼heterogeneity; HF¼hot
flushes; MSP¼muscolo-skeletal pain; ORR¼overall response rate; OS¼overall
survival; Pts¼patients; RCTs¼randomised clinical trials; REM¼random effects
model; RR¼relative risk ratio; TE: thromboembolic events; VB: vaginal bleeding.
Citation Year NTotal
Thurlimann
Nabholtz
Bonneterre
Mouridsen
Paridaens
1996
2000
2000
2001
2003
2004
212
353
668
907
238
371
2749
2749
Fixed
Random
Combined
Combined
P-value
0.074
0.107
0.155
0.283
0.006
0.693
0.012
0.021
0.01 0.1 1 100 10
Favours TAM Favours AI
Milla-Santos
Figure 3 Aromatase inhibitors vs tamoxifen: TEs. AI: aromatase inhibitors; TAM: tamoxifen; Ntot: total number of patients; RR: relative risk; Fixed: fixed
effects model; Random: random effects model.
Citation Year NTotal
Nabholtz
Bonneterre
Paridaens
2000
2000
2003
2004
353
668
238
371
1630
1630
Fixed
Random
Combined
Combined
P-value
0.219
0.002
0.180
0.179
0.001
0.001
0.01 0.1 1 100 10
Favours TAM Favours AI
Milla-Santos
Figure 4 Aromatase inhibitors vs tamoxifen: VB. AI: aromatase inhibitors; TAM: tamoxifen; Ntot: total number of patients; RR: relative risk; Fixed: fixed
effects model; Random: random effects model.
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s2). Stratifying for type of AI (steroidal and non-steroidal), a
significant difference (FEM) in ORR, CB, and TTP in favour of
nsAI over Tam was observed as well. At the REM, only the
improvement in CB was confirmed, whereas the advantage in TTP
lost its significance (Table 3). Fadrozole (Tominaga et al, 2003)
and formestane (Vorobiof et al, 1999) have been shown to be
inferior to letrozole and anastrozole, respectively. For this reason,
we excluded fadrozole and formestane studies from the analysis of
AI vs Tam, in order to make the differences greater. Comparing
tgAI vs Tam, a significant difference (FEM) in ORR, CB, and TTP
in favour of tgAI over Tam was observed. It must be highlighted
that the results concerning TTP and CB maintained their
significance at the REM, despite the significant heterogeneity
(Table 4). By contrast, there was no clear evidence of benefit in
OS comparing AI with Tam, without significant heterogeneity.
However, OS estimation in MBC could be affected by several
factors, such as prior or subsequent chemotherapy or hormonal
treatments or crossover design, and TTP might be regarded as the
most sensitive parameter to assess efficacy of a new drug,
especially when TTP increase is associated with ORR increase
(Di Leo and Bleiberg, 2003). Finally, owing to the above-mentioned
significant heterogeneity, any definitive conclusion about ORR,
TTP, and CB cannot be conclusively affirmed.
The availability of results using both the REM and FEM in
electronic publications could represent a temptation to select the
model that better supports the authors’ hypothesis, introducing a
potential source of bias in the interpretation of meta-analysis
results. Heterogeneity is an important issue in meta-analyses.
When there is no component of variability between studies, the
results of methods based on FEM or REM are essentially identical
and both methods yield similar point estimates (Greenland, 1987;
Berlin et al, 1989). When there is heterogeneity between studies,
fixed effects standard errors often suggest inappropriate precision
and the CI for a summary estimate of effects size will be wider
when the random effect is used. Thus, as heterogeneity is
incorporated directly into random effects summary estimates
and their standard errors, it is not surprising that random effects
estimates sometimes differ from corresponding fixed effects ones
(Engels et al, 2000). The overall effect of heterogeneity could be to
make most random effects estimates less significant than the
corresponding fixed effects estimates. The REM assumption that
trials included in a meta-analysis are a random sample from a large
population of trials would seem to be less defendable in the context
of systematic reviews, which, by definition, aim at the inclusion of
all published and unpublished trials considered as the population
from which this assumption is being inferred (Villar et al, 2001).
The REM inference concerning parameters of a population larger
than those trials available, including trials that may be carried out
later, does not seem relevant in the context of meta-analyses
conducted as part of systematic reviews of randomised controlled
trials. Such reviews explore mostly the question as to whether the
treatment can produce benefit on average in the studies at hand
(Bailey, 1987). Finally, several authors present arguments for and
against routine use of models based on REM or FEMs in meta-
analysis (Greenland, 1987; Peto, 1987; Berlin et al, 1989; Thompson
and Pocock, 1991), but there is no clear consensus yet.
Heterogeneity is not only statistical per se, but is also closely
related to the study design of the systematic review, the nature of
the trials included, the intended extrapolation of the results, and
the clinical relevance of the observed differences. Therefore,
systematic reviews might locate all available trials (even if
unpublished) and make extensive efforts to include them, similar
to the efforts typically made to reduce loss to follow-up in clinical
trials. In the presence of statistical heterogeneity, the main focus of
a meta-analysis should be on trying to understand clinical sources
of heterogeneity. The significant heterogeneity, which proves trial
interaction, could easily depend on different patients selection (i.e.,
differences in the characteristics of study subjects, such as their
mean age and the severity of illness, positive or unknown receptor
status, node-negative or node-positive disease), different trial
designs, different rates of loss to follow-up, different interventions
(dose or duration of treatment), or outcome measures. For
example, the study by Mouridsen et al (2001) had almost twice
as many patients with prior Tam therapy than the study by
Bonneterre et al (2000) and Nabholtz et al (2000) (22 vs 7.6 vs
11.6% total) (Copur et al, 2001). In four studies (Falkson and
Falkson, 1996; Thurlimann et al, 1996; Mouridsen et al, 2001;
Paridaens et al, 2004), more than 30% of the patients had
previously received chemotherapy, whereas in other three studies
(Falkson and Falkson, 1996; Bonneterre et al, 2000; Nabholtz et al,
Table 6 Toxicity: non-steroidal aromatase inhibitors vs tamoxifen (FEM and REM)
RCTs Pts RR (FEM) RR (REM) 95% CI (FEM) 95% CI (REM) P (FEM) Het. P (REM)
HF 4 2166 1.13 1.01 0.95, 1.33 0.69, 1.43 0.160 0.01 0.95
Nausea 3 1928 0.94 0.78, 1.13 0.530 0.85
Vomiting 2 1021 1.09 0.71, 1.68 0.692 0.52
TE 4 2166 0.55 0.35, 0.86 0.009 0.43
VB 3 1259 0.33 0.17, 0.65 0.001 0.71
MSP 3 1928 1.05 0.87, 1.26 0.598 0.79
CI¼confidence intervals; FEM¼fixed effects model; Het¼heterogeneity; HF¼hot flushes; MSP¼muscolo-skeletal pain; ORR¼overall response rate; OS¼overall survival;
Pts¼patients; RCTs¼randomised clinical trials; REM¼random effects model; RR¼relative risk ratio; TE¼thromboembolic events; VB¼vaginal bleeding.
Table 7 Toxicity: third-generation aromatase inhibitors vs tamoxifen (FEM and REM)
RCTs Pts RR (FEM) RR (REM) 95% CI (FEM) 95% CI (REM) P (FEM) Het. P (REM)
HF 5 2537 1.07 1.01 0.93, 1.23 0.76, 1.35 0.352 0.02 0.91
Nausea 4 2299 0.92 0.78, 1.09 0.381 0.91
Vomiting 3 1392 1.14 0.78, 1.64 0.487 0.75
TE 5 2537 0.60 0.39, 0.92 0.021 0.37
VB 4 1630 0.36 0.20, 0.64 0.0006 0.82
MSP 4 2299 1.01 0.87, 1.18 0.823 0.83
CI¼confidence intervals; FEM¼fixed effects model; Het¼heterogeneity; HF¼hot flushes; MSP¼muscolo-skeletal pain; ORR¼overall response rate; OS¼overall survival;
Pts¼patients; RCTs¼randomised clinical trials; REM¼random effects model; RR¼relative risk ratio; TE¼thromboembolic events; VB¼vaginal bleeding.
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s2000), this percentage ranged between 5 and 21%. In five trials
(Thurlimann et al, 1996; Nabholtz et al, 2000; Mouridsen et al,
2001; Milla-Santos et al, 2003; Paridaens et al, 2004), more than
65% of the patients had hormone receptor-positive tumours
compared with only 43% in the three remainder studies (Perez
Carrion et al, 1994; Falkson and Falkson, 1996; Bonneterre et al,
2000). Conversely, most of the patients in the study by Bonneterre
et al (2000) (54.4% in the anastrozole group and 55.8% in the
tamoxifen group) had tumours with unknown hormone receptors,
whereas Nabholtz et al (2000) reported only 11.1 and 11% and
Mouridsen et al (2001) 34 and 33%, respectively (Costa and
Kaufmann, 2001). Almost 50% of the patients in the study by
Bonneterre et al (2000) had advanced-stage disease at presentation
and therefore had received no prior treatment. This is 20% more
than for the women in the North American study (Nabholtz et al,
2000) and 25% more than for patients in the Mouridsen et al’s
(2001) study. The group of patients in the study by Bonneterre
et al (2000) had 88% measurable disease, compared with 68–76%
measurable disease as in the North American patients (Nabholtz
et al, 2000). More importantly, in Nabholtz et al’s (2000) study, the
tamoxifen group had an excess of patients with liver disease
(16.5%) (Tonkin, 2001) compared with Bonneterre et al’s (2000)
study (9.5%) and Mouridsen et al’s (2001) study (viscera only
13%).
Concerning toxicity, we chose the most frequently reported
side effects (at least in three trials), in order to obtain reliable
comparisons between AI and Tam. Thus, toxicity was not
evaluated completely, and, for this reason, the reported results
must be interpreted cautiously. The analysed adverse events were
HF, N, V, TEs, VB, and MSP. Thromboembolic phenomena and VB
were observed more commonly in Tam-treated patients compared
with those receiving AI (P¼0.01 and P¼0.001, respectively),
without significant heterogeneity. No significant difference was
present between AI vs Tam in terms of HF, N, V, and MSP, without
significant heterogeneity. Our findings resembled those already
reported in the literature, TE and VB being more frequent with the
use of Tam.
Based on the presented results, AI appear to be superior to Tam
as first-line endocrine option in postmenopausal women with
MBC, as a significant benefit in terms of ORR, CB, and TTP was
observed in favour of AI over Tam with fixed effects estimates.
Owing to a component of variability between the six studies
analysed, the random effects estimates differed from correspond-
ing fixed ones. Concerning the toxicity profile, AI, as expected,
caused less thromboembolic phenomena and VB than Tam.
Considering our findings, it would be crucial to analyse the
cost–utility balance of AI compared with Tam as first-line
endocrine treatment of MBC. It has been recently reported
(Dranitsaris et al, 2003; Marchetti et al, 2004) that tgAI represent
an economically acceptable alternative to Tam. Although investi-
gators should assess heterogeneity of trial results before deriving
summary estimates of treatment effect, we think that these findings
might be taken into account in the oncology practice during the
clinical decision-making process.
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